Long-term sickness absence for psychiatric disorder (LTSAP) (1990 and 2000) and mortality (all-cause, cardiovascular disease (CVD), cancer, suicide) (1991–1997 and 2000–2007).

<p>Flexible parametric survival models with hazard ratios (HR) and 95% confidence intervals (CI). The reference group comprises those with no registered sickness absence (SA) (1990 and 2000). Model 1: Crude; Model 2: Adjusted for age, sex, education, country of origin, family situation, and inpatient care due to somatic diagnoses and psychiatric diagnoses. *All-cause mortality and suicide deaths adjusted for age, sex, education, country of origin, family situation, and inpatient care due to somatic diagnoses, psychiatric diagnoses and suicide attempt.</p

Long-term sickness absence for psychiatric disorder (LTSAP) (1990) and mortality (all-cause, cardiovascular disease (CVD), cancer, suicide) (1991–2007).

<p>Flexible parametric survival models with hazard ratios (HR) and 95% confidence intervals (CI). The reference group comprises those with no registered sickness absence (SA) (1990). Model 1: Crude; Model 2: Adjusted for age, sex, education, country of origin, family situation; Model 3: Adjusted for the covariates in model 2 and inpatient care due to somatic diagnoses; Model 4: Adjusted for the covariates in model 3 and inpatient care due to psychiatric diagnoses. *All-cause mortality and suicide deaths adjusted for the covariates in model 3 and inpatient care due to psychiatric diagnoses and suicide attempt.</p

Long-term sickness absence for psychiatric disorders (1990) and all-cause mortality (199106–200712).

<p>Hazard ratio (HR) and 95% confidence interval (CI) (HR = black line and CI = shaded area) from time-dependent flexible parametric survival model adjusted for age, sex, education, country of origin, family situation, and previous inpatient care. Black line at vertical number 1 means no association.</p

Summary Generalized Estimation Equation (GEE) model.

<p>Summary Generalized Estimation Equation (GEE) model.</p

Criteria for Exhaustion Disorder according to the Swedish National Board of Health and Welfare^a.

<p>Criteria for Exhaustion Disorder according to the Swedish National Board of Health and Welfare<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153924#t001fn001" target="_blank">^a</a>.</p

Median regression of possible confounders for plasma levels of VEGF, EGF and MCP-1 at baseline (T0) in women with exhaustion disorder.

<p>Median regression of possible confounders for plasma levels of VEGF, EGF and MCP-1 at baseline (T0) in women with exhaustion disorder.</p

Box plots for plasma levels of VEGF, EGF and MCP-1 in controls and patients.

<p>Box plot for plasma levels of VEGF, EGF and MCP-1 in controls and patients at baseline (T0), after 12 months (T12) and after 24 months (T24). P-values refer to plasma levels of VEGF, EGF and MCP-1 in controls compared to time of follow up (T0, T12 or T24) in patients.</p

Flowchart of inclusion of controls.

<p>Flowchart of inclusion of controls.</p

Flowchart of inclusion of patients.

<p>Flowchart of inclusion of patients.</p

Descriptive characteristics of patients and controls.

<p>Descriptive characteristics of patients and controls.</p